IONS - Ionis licenses two candidates to Roche for Alzheimer's Huntington's
2023-09-27 10:25:40 ET
More on Ionis Pharmaceuticals, Roche
- Roche: Positive Readouts From Pipeline
- Roche: 2023 Should Mark The Bottom
- Ionis Pharmaceuticals: Mid-Sized Pharma Is A Strong Buy Opportunity For All-Comers
- Ionis late-stage rare disease data fails to impress Bernstein
- Ionis succeeds in Phase 3 trial for rare disease drug
For further details see:
Ionis licenses two candidates to Roche for Alzheimer's, Huntington's